A Comparative Study On The Efficacy And Safety And Index Of Metabolization Of Ziprasidone And Risperidone For Schizophrenic Patients

ObjectiveTo evaluate the the efficacy and safety and index of metabolization of ziprasidone and risperidone for schizophrenic patients.MethodsA total of 100 patients with schizophrenia were randomly divided into study group with ziprasidone (n=50) and control group with risperidone (n=50) for treatment of 8 weeks. By the end of the treatment,two patients in study group came off,and three patients in control group came off.They were evaluated with PANSS, CGI and CDSS for clinical efficacy, TESS,RSESE for safety at the baseline, the 2nd weekend,the 4th weekend and 8th weekend, and ECG,fasting blood sugar,blood cholesterol, blood triglyceride,Serum prolactin levels and body weight for safety and index of metabolization at the baseline, the 4th weekend and 8th weekend.All statistical analyses were performed using SPSS 13.0 software.Two-sample/group t-test for independent samples and paired samples, ANOVA were applied in this study.Results1.The total scores and factors scores of positive and negative symptom scale(PANSS) in the study group and control group were no significant differences at the baseline(P>0.05)and after treatment(P>0.05).And the total scores and factors scores of PANSS were significant lower(P<0.05 or P< 0.01)after treatment at the 2nd weekend,4th weekend,6th weekend and 8th weekend than those at the baseline.2.The scores of Calgary Depression Scale for Schizophrenia(CDSS) in both groups were no significant differences at the baseline(P>0.05)and the same times after treatment(P>0.05).The scores of CDSS in both groups were significantly lower at the 2nd weekend,4th weekend,6th weekend and 8th weekend than those at the baseline.3.The side effects in two groups were mild in both groups at the baseline(P >0.05).There were no significant differences for adverse effect rate in both groups(P>0.05).4.There were no significant differences on body weight,blood sugar, blood cholesterol and blood triglyceride in patients in two groups at the baseline (P>0.05).And there were no significant differences on all of the above factors in study group at the 4th weekend and 8thweekend(P>0.05).But in control group there were significant differences on body weight at the 4th weekend and 8th weekend after treatment compared with those at the baseline (P<0.05),and no significant differences on blood sugar,blood cholesterol and blood triglyceride. Both of the above factors were no significant differences at the baseline and after treatment in both groups(P>0.05).5.At the 4th weekend and 8th weekend after treatment, there were no significant differences for serum prolactin in study group compared with those at the baseline (P>0.05).But at the 4th weekend and 8th weekend after treatment,the serum prolactin in control group were both significantly higher than those at the baseline (P<0.01),The serum prolactin in control group after treatment were all significantly higher than those in study group at the same times(P<0.01).Conclusions1.Both ziprasidone and risperidone are effective in the treatment of patients with schizophrenia.2.Both ziprasidone and risperidone are effective in the treatment of depressive symptoms in patients with schizophrenia.3.Both ziprasidone and risperidone with mild side-effects are effective and safe in the treatment of patients with schizophrenia.4.The effects on body weight,blood sugar,blood lipid and serum prolactin in patients with ziprasidone are light.5.Ziprasidone is available especially for the fats or those with higher blood sugar, blood lipid,higher serum prolactin,those unmarried or unborn.